{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:00:11Z","timestamp":1791234011872,"version":"4.1.0"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.eclinm.2026.103990","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:27:06Z","timestamp":1780104426000},"page":"103990","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Beta-blocker therapy after myocardial infarction: an umbrella review"],"prefix":"10.1016","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6297-9109","authenticated-orcid":false,"given":"Pilar","family":"Cataldo-Miranda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuong Khanh","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey Jia Wei","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danijela","family":"Gasevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri","family":"Chodapuneedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amminadab L.","family":"Eliakundu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dion","family":"Stub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Zoungas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Talic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2026.103990_bib1","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","article-title":"Global burden of cardiovascular diseases and risks, 1990-2022","volume":"82","author":"Mensah","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.eclinm.2026.103990_bib2","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1161\/01.CIR.66.6.1179","article-title":"Timolol-related reduction in mortality and reinfarction in patients ages 65-75 years surviving acute myocardial infarction. Prepared for the Norwegian Multicentre Study Group","volume":"66","author":"Gundersen","year":"1982","journal-title":"Circulation"},{"key":"10.1016\/j.eclinm.2026.103990_bib3","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0140-6736(81)91101-6","article-title":"Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial","volume":"318","author":"Hjalmarson","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2026.103990_bib4","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.1982.03320370021023","article-title":"A randomized trial of propranolol in patients with acute myocardial infarction: I. Mortality results","volume":"247","year":"1982","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2026.103990_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0140-6736(86)91607-7","article-title":"Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1","volume":"328","author":"Friedman","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2026.103990_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101582","article-title":"Beta-blocker therapy after myocardial infarction","volume":"4","author":"Cataldo Miranda","year":"2025","journal-title":"JACC Adv"},{"key":"10.1016\/j.eclinm.2026.103990_bib7","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.amjmed.2014.05.032","article-title":"Clinical outcomes with \u03b2-Blockers for myocardial infarction: a meta-analysis of randomized trials","volume":"127","author":"Bangalore","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.eclinm.2026.103990_bib8","author":"Cataldo Miranda"},{"key":"10.1016\/j.eclinm.2026.103990_bib9","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2026.103990_bib10","author":"Gates"},{"key":"10.1016\/j.eclinm.2026.103990_bib12","series-title":"Joanna Briggs Institute 2017 Critical Appraisal Checklist for Systematic Reviews and Research Syntheses","author":"Martin","year":"2017"},{"key":"10.1016\/j.eclinm.2026.103990_bib14","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1007\/s40279-024-02099-w","article-title":"Impact of sedentary behaviors on blood pressure and cardiovascular disease: an umbrella review of systematic reviews and meta-analyses","volume":"54","author":"O'Brien","year":"2024","journal-title":"Sports Med"},{"key":"10.1016\/j.eclinm.2026.103990_bib15","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2026.103990_bib16","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2026.103990_bib17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1016\/j.eclinm.2026.103990_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/ebmental-2018-300014","article-title":"Ten simple rules for conducting umbrella reviews","volume":"21","author":"Fusar-Poli","year":"2018","journal-title":"Evid Based Ment Health"},{"key":"10.1016\/j.eclinm.2026.103990_bib19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","article-title":"Meta-analysis in clinical trials revisited","volume":"45","author":"DerSimonian","year":"2015","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.eclinm.2026.103990_bib20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2026.103990_bib21","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/sim.1187","article-title":"How should meta-regression analyses be undertaken and interpreted?","volume":"21","author":"Thompson","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.eclinm.2026.103990_bib22","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.eclinm.2026.103990_bib24","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12874-021-01269-y","article-title":"Managing overlap of primary study results across systematic reviews: practical considerations for authors of overviews of reviews","volume":"21","author":"Lunny","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.eclinm.2026.103990_bib25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/aphw.12169","article-title":"Best practice guidelines and essential methodological steps to conduct rigorous and systematic meta-reviews","volume":"11","author":"Hennessy","year":"2019","journal-title":"Appl Psychol Health Well-Being"},{"key":"10.1016\/j.eclinm.2026.103990_bib26","series-title":"Introduction to Meta-Analysis","first-page":"45","article-title":"Converting among effect sizes","author":"Borenstein","year":"2009"},{"key":"10.1016\/j.eclinm.2026.103990_bib28","series-title":"GRADE Book version 1.0","year":"2024"},{"key":"10.1016\/j.eclinm.2026.103990_bib29","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/ehjcvp\/pvy034","article-title":"Effect of oral \u03b2-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis","volume":"5","author":"Dahl Aarvik","year":"2019","journal-title":"Eur Heart J \u2014 Cardiovasc Pharmacother"},{"key":"10.1016\/j.eclinm.2026.103990_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.779462","article-title":"Long-term effect of \u03b2-Blocker use on clinical outcomes in postmyocardial infarction patients: a systematic review and meta-analysis","volume":"9","author":"Liang","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.eclinm.2026.103990_bib31","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/FJC.0000000000001221","article-title":"Long-term beta-blocker therapy after myocardial infarction without heart failure in the reperfusion era\u2014systemic review and meta-analysis","volume":"79","author":"Kim","year":"2022","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.eclinm.2026.103990_bib32","first-page":"CD012565","article-title":"Beta-blockers in patients without heart failure after myocardial infarction","volume":"2021","author":"Safi","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eclinm.2026.103990_bib33","article-title":"Beta-blockers for suspected or diagnosed acute myocardial infarction","volume":"12","author":"Safi","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eclinm.2026.103990_bib34","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3390\/jcm14010150","article-title":"Beta-blockers in patients with myocardial infarction and preserved left ventricular ejection: a systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Sabina","year":"2024","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.eclinm.2026.103990_bib35","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1056\/NEJMoa2512686","article-title":"Beta-blockers after myocardial infarction with normal ejection fraction","volume":"394","author":"Kristensen","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.103990_bib36","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/S0140-6736(25)01592-2","article-title":"\u03b2 blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials","volume":"406","author":"Rossello","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2026.103990_bib37","author":"Sidiq"},{"key":"10.1016\/j.eclinm.2026.103990_bib38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.amjcard.2024.10.027","article-title":"Role of beta blockers after acute coronary syndrome with preserved ejection fraction","volume":"235","author":"Singh","year":"2025","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.eclinm.2026.103990_bib39","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/eurjpc\/zwae298","article-title":"Beta-blockers for secondary prevention following myocardial infarction in patients without reduced ejection fraction or heart failure: an updated meta-analysis","volume":"32","author":"Chi","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.eclinm.2026.103990_bib40","doi-asserted-by":"crossref","first-page":"398","DOI":"10.21037\/cdt-24-368","article-title":"Beta-blockers in post-myocardial infarction with preserved ejection fraction: systematic review and meta-analysis","volume":"15","author":"Gomes","year":"2025","journal-title":"Cardiovasc Diagn Ther"},{"key":"10.1016\/j.eclinm.2026.103990_bib41","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.acvd.2022.09.004","article-title":"Association of beta-blocker therapy at discharge with clinical outcomes in patients without heart failure or left ventricular systolic dysfunction after acute coronary syndrome: an updated systematic review and meta-analysis","volume":"115","author":"Hu","year":"2022","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.eclinm.2026.103990_bib42","article-title":"Beta-blocker use after discharge in patients with acute myocardial infarction in the contemporary reperfusion era","volume":"58","author":"Hu","year":"2022","journal-title":"Med Kaunas Lith"},{"key":"10.1016\/j.eclinm.2026.103990_bib43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/FJC.0000000000000922","article-title":"Efficacy of long-term oral beta-blocker therapy in patients who underwent percutaneous coronary intervention for ST-Segment elevation myocardial infarction with preserved left ventricular ejection fraction: a systematic review and meta-analysis","volume":"77","author":"Maqsood","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.eclinm.2026.103990_bib44","article-title":"Prophylactic beta-blocker therapy in patients who underwent primary percutaneous coronary intervention for ST-Elevation myocardial infarction with preserved left ventricular ejection fraction: a systematic review and meta-analysis","volume":"17","author":"Affas","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.eclinm.2026.103990_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14113969","article-title":"Exploring the impact of beta-blockers post-acute myocardial infarction in patients with preserved ejection fraction: a meta-analysis","volume":"14","author":"Alnemer","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.eclinm.2026.103990_bib46","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1007\/s00228-025-03919-2","article-title":"\u03b2-blocker and clinical outcomes in patients after myocardial infarction: a systematic review and meta-analysis","volume":"81","author":"Yang","year":"2025","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.eclinm.2026.103990_bib47","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.clinthera.2025.06.007","article-title":"The role of oral \u03b2-Blockers in patients with acute myocardial infarction with preserved or mildly reduced left ventricular systolic function: a systematic review and meta-analysis","volume":"47","author":"Chen","year":"2025","journal-title":"Clin Ther"},{"key":"10.1016\/j.eclinm.2026.103990_bib48","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.amjcard.2023.04.042","article-title":"Effects of long-term carvedilol therapy in patients with ST-Segment elevation myocardial infarction and mildly reduced left ventricular ejection fraction","volume":"199","author":"Amano","year":"2023","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.eclinm.2026.103990_bib49","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1161\/CIRCOUTCOMES.114.001073","article-title":"\u03b2-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial","volume":"7","author":"Bangalore","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.eclinm.2026.103990_bib50","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial","volume":"357","author":"Dargie","year":"2001","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.eclinm.2026.103990_bib51","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00380-015-0673-1","article-title":"Impact of oral beta-blocker therapy on mortality after primary percutaneous coronary intervention for Killip class 1 myocardial infarction","volume":"31","author":"Hioki","year":"2016","journal-title":"Heart Vessel"},{"issue":"19","key":"10.1016\/j.eclinm.2026.103990_bib52","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa2504735","article-title":"Beta-blockers after myocardial infarction without reduced ejection fraction","volume":"393","author":"Ibanez","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.103990_bib53","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jacc.2004.09.076","article-title":"Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the carvedilol post-infarct survival control in left ventricular dysfunction (CAPRICORN) trial","volume":"45","author":"McMurray","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.eclinm.2026.103990_bib54","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1056\/NEJMoa2505985","article-title":"Beta-blockers after myocardial infarction in patients without heart failure","volume":"393","author":"Munkhaugen","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.103990_bib55","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa2404204","article-title":"Beta-blocker interruption or continuation after myocardial infarction","volume":"391","author":"Silvain","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.103990_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199347","article-title":"Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention","volume":"13","author":"Watanabe","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.eclinm.2026.103990_bib57","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1056\/NEJMoa2401479","article-title":"Beta-blockers after myocardial infarction and preserved ejection fraction","volume":"390","author":"Yndigegn","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.103990_bib58","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001611","article-title":"\u03b2-Blocker use and mortality in COPD patients after myocardial infarction: a Swedish nationwide observational study","volume":"4","author":"Andell","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.eclinm.2026.103990_bib59","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1157\/13087059","article-title":"Effect of combined beta-blocker and angiotensin-converting enzyme inhibitor treatment on 1-year survival after acute myocardial infarction: findings of the PRIAMHO-II registry","volume":"59","author":"Ar\u00f3s","year":"2006","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.eclinm.2026.103990_bib60","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s12928-012-0137-9","article-title":"\u03b2-Blocker therapy and cardiovascular outcomes in patients who have undergone percutaneous coronary intervention after ST-elevation myocardial infarction","volume":"28","author":"Bao","year":"2013","journal-title":"Cardiovasc Interv Ther"},{"key":"10.1016\/j.eclinm.2026.103990_bib61","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4351469","article-title":"Association of \u03b2-blocker therapy at discharge with clinical outcomes after acute coronary syndrome in patients without heart failure","volume":"2020","author":"Chen","year":"2020","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.eclinm.2026.103990_bib62","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.amjcard.2005.05.025","article-title":"Impact of beta-blocker therapy at discharge on long-term mortality after primary angioplasty for ST-segment elevation myocardial infarction","volume":"96","author":"De Luca","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.eclinm.2026.103990_bib63","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1016\/j.jacc.2017.03.578","article-title":"\u03b2-Blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction","volume":"69","author":"Dondo","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.eclinm.2026.103990_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjcard.2020.12.044","article-title":"Comparison of outcomes with or without beta-blocker therapy after acute myocardial infarction in patients without heart failure or left ventricular systolic dysfunction (from the Acute Coronary Syndromes Israeli Survey [ACSIS])","volume":"143","author":"El Nasasra","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.eclinm.2026.103990_bib65","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/eurheartj\/ehaa1058","article-title":"Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study","volume":"42","author":"Holt","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.eclinm.2026.103990_bib66","first-page":"410","article-title":"Prognostic impact of \u03b2-blocker dose after acute myocardial infarction","volume":"83","author":"Hwang","year":"2019","journal-title":"Circ J Off J Jpn Circ Soc"},{"key":"10.1016\/j.eclinm.2026.103990_bib67","first-page":"1159","article-title":"Association of beta-blockers beyond 1 year after myocardial infarction and cardiovascular outcomes","volume":"109","author":"Ishak","year":"2023","journal-title":"Heart Br Card Soc"},{"key":"10.1016\/j.eclinm.2026.103990_bib68","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1536\/jhj.41.279","article-title":"beta-blockers reduce the incidence of cardiac events in post-myocardial infarction patients","volume":"41","author":"Ishikawa","year":"2000","journal-title":"Jpn Heart J"},{"key":"10.1016\/j.eclinm.2026.103990_bib69","first-page":"1633","article-title":"Clinical outcomes with beta-blocker use in patients with recent history of myocardial infarction","volume":"36","author":"Jackevicius","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.eclinm.2026.103990_bib70","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000431077","article-title":"\u03b2-Blocker therapy in the era of primary percutaneous intervention for ST elevation myocardial infarction","volume":"132","author":"Lee","year":"2015","journal-title":"Cardiology"},{"key":"10.1016\/j.eclinm.2026.103990_bib71","article-title":"Effect of beta blockers and renin-angiotensin system inhibitors on survival in patients with acute myocardial infarction undergoing percutaneous coronary intervention","volume":"95","author":"Lee","year":"2016","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.eclinm.2026.103990_bib72","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1253\/circj.CJ-18-0995","article-title":"Admission heart rate is a determinant of effectiveness of beta-blockers in acute myocardial infarction patients","volume":"83","author":"Okuno","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.eclinm.2026.103990_bib73","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.amjcard.2010.06.048","article-title":"Lack of effect of oral beta-blocker therapy at discharge on long-term clinical outcomes of ST-segment elevation acute myocardial infarction after primary percutaneous coronary intervention","volume":"106","author":"Ozasa","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.eclinm.2026.103990_bib74","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.mayocp.2019.05.033","article-title":"Differential effect of \u03b2-blockers according to heart rate in acute myocardial infarction without heart failure or left ventricular systolic dysfunction: a cohort study","volume":"94","author":"Park","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.eclinm.2026.103990_bib75","first-page":"728","article-title":"Role of beta blockers following percutaneous coronary intervention for acute coronary syndrome","volume":"107","author":"Peck","year":"2021","journal-title":"Heart Br Card Soc"},{"key":"10.1016\/j.eclinm.2026.103990_bib76","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0140-6736(00)02606-4","article-title":"Rate of heart failure and 1-year survival for older people receiving low-dose \u03b2-blocker therapy after myocardial infarction","volume":"356","author":"Rochon","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2026.103990_bib77","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jjcc.2022.08.002","article-title":"Clinical impact of beta-blockers at discharge on long-term clinical outcomes in patients with non-reduced ejection fraction after acute myocardial infarction","volume":"81","author":"Sakagami","year":"2023","journal-title":"J Cardiol"},{"key":"10.1016\/j.eclinm.2026.103990_bib78","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.005103","article-title":"Comparative effectiveness of \u03b2-blocker use beyond 3 years after myocardial infarction and long-term outcomes among elderly patients","volume":"12","author":"Shavadia","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.eclinm.2026.103990_bib79","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1540-8159.2010.02694.x","article-title":"Beta-blocker in post-myocardial infarct survivors with preserved left ventricular systolic function","volume":"33","author":"Siu","year":"2010","journal-title":"Pacing Clin Electrophysiol PACE"},{"key":"10.1016\/j.eclinm.2026.103990_bib80","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1007\/s00380-021-01876-1","article-title":"Heart failure with mid-range ejection fraction and the effect of \u03b2-blockers after acute myocardial infarction","volume":"36","author":"Song","year":"2021","journal-title":"Heart Vessel"},{"key":"10.1016\/j.eclinm.2026.103990_bib81","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijcard.2005.05.015","article-title":"Effect of beta-blockers on the mortality of Japanese patients with myocardial infarction","volume":"108","author":"Yamada","year":"2006","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.eclinm.2026.103990_bib82","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jama.2012.12559","article-title":"\u03b2-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease","volume":"308","author":"Bangalore","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2026.103990_bib83","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40256-018-0273-4","article-title":"Association of beta-blockers with survival on patients presenting with ACS treated with PCI: a propensity score analysis from the BleeMACS registry","volume":"18","author":"D'Ascenzo","year":"2018","journal-title":"Am J Cardiovasc Drugs Drugs Devices Interv"},{"key":"10.1016\/j.eclinm.2026.103990_bib84","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000030846","article-title":"Association of the medical therapy with beta-blockers or inhibitors of renin-angiotensin system with clinical outcomes in patients with mildly reduced left ventricular ejection fraction after acute myocardial infarction","volume":"101","author":"Joo","year":"2022","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.eclinm.2026.103990_bib85","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00380-014-0624-2","article-title":"Long-term effect of \u03b2-blocker in ST-segment elevation myocardial infarction in patients with preserved left ventricular systolic function: a propensity analysis","volume":"31","author":"Konishi","year":"2016","journal-title":"Heart Vessel"},{"key":"10.1016\/j.eclinm.2026.103990_bib86","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-79214-0","article-title":"Beta-blockers provide a differential survival benefit in patients with coronary artery disease undergoing contemporary post-percutaneous coronary intervention management","volume":"10","author":"Lee","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.eclinm.2026.103990_bib87","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.recesp.2014.07.029","article-title":"Prognostic benefit of beta-blockers after acute coronary syndrome with preserved systolic function. Still relevant today?","volume":"68","author":"Raposeiras-Roub\u00edn","year":"2015","journal-title":"Rev Espanola Cardiol Engl Ed"},{"key":"10.1016\/j.eclinm.2026.103990_bib88","doi-asserted-by":"crossref","first-page":"499","DOI":"10.4070\/kcj.2019.0231","article-title":"Clinical impact of beta blockers in patients with myocardial infarction from the Korean national health insurance database","volume":"50","author":"Won","year":"2020","journal-title":"Korean Circ J"},{"key":"10.1016\/j.eclinm.2026.103990_bib89","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1177\/00033197241227025","article-title":"The effect of beta-blocker post-myocardial infarction with ejection fraction >40% pooled analysis from seven arabian gulf acute coronary syndrome registries","volume":"76","author":"Al-Bawardy","year":"2025","journal-title":"Angiology"},{"key":"10.1016\/j.eclinm.2026.103990_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105614","article-title":"Prognostic impacts of \u03b2-blockers in acute coronary syndrome patients without heart failure treated by percutaneous coronary intervention","volume":"169","author":"Chen","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.eclinm.2026.103990_bib91","first-page":"492","article-title":"Benefit of \u03b2-blocker treatment for patients with acute myocardial infarction and preserved systolic function after percutaneous coronary intervention","volume":"100","author":"Choo","year":"2014","journal-title":"Heart Br Card Soc"},{"key":"10.1016\/j.eclinm.2026.103990_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1447952","article-title":"Beta-blockers after percutaneous coronary intervention for acute myocardial infarction and non-reduced left ventricular ejection fraction","volume":"11","author":"Jeong","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.eclinm.2026.103990_bib93","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/ehjcvp\/pvaa029","article-title":"Effect of beta-blocker therapy in patients with or without left ventricular systolic dysfunction after acute myocardial infarction","volume":"7","author":"Joo","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.eclinm.2026.103990_bib94","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.amjcard.2012.10.026","article-title":"Impact of beta blockade therapy on long-term mortality after ST-segment elevation acute myocardial infarction in the percutaneous coronary intervention era","volume":"111","author":"Nakatani","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.eclinm.2026.103990_bib95","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007567","article-title":"Effect of \u03b2-Blockers beyond 3 years after acute myocardial infarction","volume":"7","author":"Park","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.eclinm.2026.103990_bib96","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.120.010159","article-title":"Left ventricular ejection fraction 1 year after acute myocardial infarction identifies the benefits of the long-term use of \u03b2-Blockers: analysis of data from the KAMIR-NIH registry","volume":"14","author":"Park","year":"2021","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.eclinm.2026.103990_bib97","article-title":"\u03b2 blockers and mortality after myocardial infarction in patients without heart failure: Multicentre prospective cohort study","volume":"354","author":"Puymirat","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2026.103990_bib98","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12872-022-02631-8","article-title":"Short-term\/long-term prognosis with or without beta-blockers in patients without heart failure and with preserved ejection fraction after acute myocardial infarction: a multicenter retrospective cohort study","volume":"22","author":"Wen","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.eclinm.2026.103990_bib99","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jcin.2013.12.206","article-title":"Association of beta-blocker therapy at discharge with clinical outcomes in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"7","author":"Yang","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.eclinm.2026.103990_bib100","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijcard.2017.01.035","article-title":"Beta-blockers reduced the risk of cardiac rupture in patients with acute myocardial infarction: a meta-analysis of randomized control trials","volume":"232","author":"Gong","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.eclinm.2026.103990_bib101","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s10741-021-10189-4","article-title":"Use of disease-modifying drugs in diabetic patients with heart failure with reduced ejection fraction","volume":"28","author":"Masarone","year":"2023","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.eclinm.2026.103990_bib102","doi-asserted-by":"crossref","DOI":"10.2174\/1573403X19666230111143901","article-title":"Role of \u03b2-blockers in preventing heart failure and major adverse cardiac events post myocardial infarction","volume":"19","author":"Johri","year":"2023","journal-title":"Curr Cardiol Rev"},{"key":"10.1016\/j.eclinm.2026.103990_bib103","doi-asserted-by":"crossref","first-page":"e674","DOI":"10.1016\/S2666-7568(22)00186-6","article-title":"Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43 895 trials and 5 685 738 individuals across 989 unique drugs and 286 conditions in England","volume":"3","author":"Tan","year":"2022","journal-title":"Lancet Healthy Longev"},{"key":"10.1016\/j.eclinm.2026.103990_bib104","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0033-0620(85)80003-7","article-title":"Beta blockade during and after myocardial infarction: an overview of the randomized trials","volume":"27","author":"Yusuf","year":"1985","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.eclinm.2026.103990_bib105","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jacep.2017.12.015","article-title":"Change in left ventricular ejection fraction following first myocardial infarction and outcome","volume":"4","author":"Chew","year":"2018","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.eclinm.2026.103990_bib106","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4330\/wjc.v12.i8.373","article-title":"Sympathetic nervous system activation and heart failure: current state of evidence and the pathophysiology in the light of novel biomarkers","volume":"12","author":"Borovac","year":"2020","journal-title":"World J Cardiol"},{"key":"10.1016\/j.eclinm.2026.103990_bib107","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.3390\/cells13201674","article-title":"Regulation of \u03b2-Adrenergic receptors in the heart: a review on emerging therapeutic strategies for heart failure","volume":"13","author":"Parichatikanond","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.eclinm.2026.103990_bib108","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13063-023-07105-6","article-title":"Mapping the methodological diversity of published drug discontinuation studies\u2014a scoping review of study topics, objectives, and designs","volume":"24","author":"Grede","year":"2023","journal-title":"Trials"},{"key":"10.1016\/j.eclinm.2026.103990_bib109","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242015472","article-title":"Neurohumoral activation in heart failure","volume":"24","author":"Manolis","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.eclinm.2026.103990_bib110","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","article-title":"AHA\/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American heart association and American college of cardiology foundation","volume":"124","author":"Smith","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.eclinm.2026.103990_bib111","first-page":"e362","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"O'Gara","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.eclinm.2026.103990_bib112","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with Non-ST-Elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association task force on practice Guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.eclinm.2026.103990_bib113","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.eclinm.2026.103990_bib114","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes: the task force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.eclinm.2026.103990_bib115","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.eclinm.2026.103990_bib116","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026002385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026002385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:29:41Z","timestamp":1791232181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026002385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":112,"alternative-id":["S2589537026002385"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103990","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beta-blocker therapy after myocardial infarction: an umbrella review","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103990","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103990"}}